| Literature DB >> 29643957 |
Tomas Dusek1,2, Julius Orhalmi1, Otakar Sotona1, Lenka Kujovska Krcmova3,4, Lenka Javorska3,4, Josef Dolejs5, Jiri Paral1,2.
Abstract
INTRODUCTION: At present, there are no strong predictors, nor a useful scoring system, that clearly identifies patients at risk for anastomotic leakage. AIM: This study aimed to investigate a new method that assesses this risk by monitoring levels of neopterin, tryptophan, and kynurenine, in bodily fluids.Entities:
Keywords: anastomotic leak; kynurenine; neopterin; rectal carcinoma; tryptophan
Year: 2018 PMID: 29643957 PMCID: PMC5890852 DOI: 10.5114/wiitm.2018.73363
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Analysis of AL per severity
| Anastomotic leak | % | |
|---|---|---|
| Type A | 7 | 43.8 |
| Type B | 5 | 31.2 |
| Type C | 4 | 25.0 |
| Total | 16 | 100.0 |
Patient demographic data
| Parameter | Without AL | AL | |||
|---|---|---|---|---|---|
| % | % | ||||
| Sex: | 0.421 | ||||
| Male | 15 | 57.7 | 12 | 75.0 | |
| Female | 11 | 42.3 | 4 | 25.0 | |
| Age: | 0.013 | ||||
| Mean | 62.2 | 68.1 | |||
| Median | 63.5 | 67 | |||
| Range | 44–75 | 58–81 | |||
| BMI: | 0.341 | ||||
| Mean | 27.8 | 27.4 | |||
| Median | 27.8 | 27.2 | |||
| Range | 21.3–34.6 | 22.4–31.9 | |||
| ASA: | 0.138 | ||||
| 1 | 1 | 3.8 | 0 | 0 | |
| 2 | 19 | 73.1 | 9 | 56.3 | |
| 3 | 6 | 23.1 | 7 | 43.7 | |
| 4 | 0 | 0 | 0 | 0 | |
| Diabetes mellitus: | 0.628 | ||||
| Positive | 2 | 7.7 | 2 | 12.5 | |
| Negative | 24 | 92.3 | 14 | 87.5 | |
| Cardiovascular comorbidity: | 0.940 | ||||
| Positive | 13 | 50.0 | 9 | 56.3 | |
| Negative | 13 | 50.0 | 7 | 43.7 | |
| Pulmonary disease: | 1.000 | ||||
| Positive | 1 | 3.8 | 0 | 0 | |
| Negative | 25 | 96.2 | 16 | 100.0 | |
| Corticoids: | N/A | ||||
| Positive | 0 | 0 | 0 | 0 | |
| Negative | 25 | 100.0 | 16 | 100.0 | |
N/A – not applicable/not available.
Data associated with tumors
| Parameter | Without AL | AL | |||
|---|---|---|---|---|---|
| % | % | ||||
| Clinical stage: | 0.454 | ||||
| I | 8 | 30.8 | 2 | 12.5 | |
| II | 2 | 7.7 | 3 | 18.8 | |
| III | 16 | 61.5 | 11 | 68.7 | |
| IV | 0 | 0 | 0 | 0 | |
| Pathologic stage | 0.298 | ||||
| Complete response: | 4 | 15.4 | 1 | 6.3 | |
| I | 13 | 50.0 | 7 | 43.7 | |
| II | 3 | 11.5 | 2 | 12.5 | |
| III | 6 | 23.1 | 6 | 37.5 | |
| IV | 0 | 0 | 0 | 0 | |
| Grade: | 0.066 | ||||
| Well-differentiated | 7 | 26.9 | 0 | 0 | |
| Moderately differentiated | 19 | 73.1 | 15 | 93.7 | |
| Poorly differentiated | 0 | 0 | 1 | 6.3 | |
| Angioinvasion: | 0.352 | ||||
| Positive | 2 | 7.7 | 3 | 18.8 | |
| Negative | 24 | 92.3 | 13 | 81.2 | |
| Lympho-angioinvasive: | 1.000 | ||||
| Positive | 3 | 11.5 | 2 | 12.5 | |
| Negative | 23 | 88.5 | 14 | 87.5 | |
| Perineural invasion: | 0.352 | ||||
| Positive | 2 | 7.7 | 3 | 18.8 | |
| Negative | 24 | 92.3 | 13 | 81.2 | |
Data associated with treatment
| Parameter | Without AL | AL | |||
|---|---|---|---|---|---|
| % | % | ||||
| Neoadjuvant therapy: | 0.988 | ||||
| w/o neoadjuvant therapy | 12 | 46.2 | 6 | 37.5 | |
| Chemoradiotherapy | 14 | 53.8 | 10 | 62.5 | |
| Tumor localization: | 0.055 | ||||
| Upper rectum | 13 | 50.0 | 3 | 18.8 | |
| Middle rectum | 10 | 38.5 | 7 | 43.7 | |
| Lower rectum | 3 | 11.5 | 6 | 37.5 | |
| Type of procedure: | 0.658 | ||||
| Open | 3 | 11.5 | 3 | 18.8 | |
| Laparoscopic | 23 | 88.5 | 13 | 81.2 | |
| Derivative stoma: | 1.000 | ||||
| Positive | 7 | 26.9 | 4 | 25.0 | |
| Negative | 19 | 73.1 | 12 | 75.0 | |
| Radicality: | 1.000 | ||||
| R0 | 25 | 96.2 | 15 | 93.7 | |
| R1 | 1 | 3.8 | 1 | 6.3 | |
| R2 | 0 | 0 | |||
| Extent of mesorectal excision: | 0.015 | ||||
| Total | 15 | 57.7 | 15 | 93.7 | |
| Partial | 11 | 42.3 | 1 | 6.3 | |
| Dissected vessel: | 0.465 | ||||
| Superior rectal artery | 21 | 80.8 | 11 | 68.8 | |
| Inferior mesenteric artery | 5 | 19.2 | 5 | 31.2 | |
Leukocyte count
| Day | Mean leukocyte count (1 × 104) | ||
|---|---|---|---|
| Without AL | AL | ||
| 2nd | 8.4 | 9.8 | 0.047 |
| 5th | 6.3 | 8.6 | 0.010 |
C-reactive protein (CRP) levels
| Day | Mean CRP level [mg/l] | ||
|---|---|---|---|
| Without AL | AL | ||
| 2nd | 79.1 | 142.4 | 0.002 |
| 5th | 31.8 | 151.9 | < 0.001 |
Results for neopterin and kynurenine in sera
| Parameter | Without AL | With AL | |||
|---|---|---|---|---|---|
| Average | SD | Average | SD | ||
| Neopterin [nmol/l] | 9.36 | 2.52 | 18.08 | 8.83 | 0.118 |
| Kynurenine initial [μmol/l] | 3.96 | 7.09 | 2.65 | 1.38 | 0.820 |
| Kynurenine [μmol/l] | 2.19 | 0.43 | 2.50 | 0.81 | 0.108 |
| Kynurenine/tryptophan initial | 115.38 | 236.96 | 59.80 | 42.93 | 0.888 |
| Kynurenine/tryptophan [μmol/mmol] | 51.80 | 16.27 | 59.55 | 18.70 | 0.089 |
Results for urinary neopterin
| Parameter | Without AL | AL | |||
|---|---|---|---|---|---|
| Average | SD | Average | SD | ||
| Neopterin initial [nmol/l] | 2526.21 | 1268.85 | 4125.06 | 4540.81 | 0.128 |
| Neopterin [nmol/l] | 2583.88 | 1700.87 | 3655.53 | 3083.19 | 0.129 |
| Neopterin/creatinine initial [μmol/mol] | 114.73 | 35.54 | 139.47 | 44.28 | 0.037 |
| Neopterin/creatinine [μmol/mol] | 142.75 | 52.91 | 185.10 | 57.96 | 0.012 |
Results for neopterin, tryptophan, and kynurenine; and their average levels in drainage fluids
| Parameter | Without AL | AL | |||
|---|---|---|---|---|---|
| Average | SD | Average | SD | ||
| Neopterin [nmol/l] | 27.89 | 11.31 | 49.03 | 37.41 | 0.048 |
| Tryptophan [μmol/l] | 71.25 | 21.82 | 76.66 | 29.58 | 0.267 |
| Kynurenine [μmol/l] | 2.85 | 1.34 | 3.40 | 1.74 | 0.282 |
| Kynurenine/tryptophan [μmol/mmol] | 53.48 | 22.58 | 55.18 | 18.37 | 0.448 |
| Neopterin/tryptophan [nmol/μmol] | 0.41 | 0.18 | 0.58 | 0.34 | 0.062 |